Nacto Pharma
Natco Pharma's Q3 consolidated net profit dips 22% yoy at Rs 62 cr
Natco Pharma on Thursday said its consolidated net profit declined by 22 per cent to Rs 62 crore for the third quarter ended December 31, 2022. The Hyderabad-based drug firm had reported a net profit of Rs 80 crore in the October-December quarter of last fiscal. Total income of the company stood at Rs 513 crore in the period under review as compared with Rs 591 crore in the year-ago period that had a one-time licensing revenue. The company's board, which met on Thursday, approved an interim dividend of Rs 1.25 per share for the quarter ended December 31, 2022. Shares of the company ended 0.38 per cent down at Rs 529.10 apiece on the BSE.
 "Natco Pharma's Q3 consolidated net profit dips 22% yoy at Rs 62 cr")
Natco Pharma consolidated net profit up 27% to Rs 80 crore in Dec quarter
The Hyderabad-based company had reported a net profit of Rs 63.4 crore in the October-December period of previous fiscal
 "Natco Pharma consolidated net profit up 27% to Rs 80 crore in Dec quarter")
Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug
Natco Pharma said its marketing partner Breckenridge Pharmaceutical received final approval from the USFDA for Pomalidomide Capsules, treatment of patients suffering from multiple myeloma cancer
 "Natco Pharma's marketing partner gets USFDA nod for cancer treatment drug")
US Patent and Trademark Office rules in Mylan's favour, invalidates Teva patent: Natco
Shares of Natco Pharma were trading 0.01 per cent up at Rs 677 on BSE
 "US Patent and Trademark Office rules in Mylan's favour, invalidates Teva patent: Natco")
